Leadership

Dr. Campbell joined Axial Therapeutics in 2017 and was appointed the company’s Chief Executive Officer in February 2021. Dr. Campbell has played a fundamental role in the company’s growth and strategy over the last 4 years. He brings more than 25 years of experience leading and building teams that have strong track records of discovering and developing novel therapeutics for the patients who need them.Prior to joining Axial, Dr. Campbell held various leadership roles at biopharmaceutical and chemical manufacturing companies, including Corden Pharma, Surface Logix and Insmed Inc.At Corden Pharma, Dr. Campbell served as Head of Product Management and Business Development for Carbohydrates and Lipids and as Head of Operations for Corden Pharma’s Woburn, MA manufacturing site.Prior to Corden Pharma, Dr. Campbell served as Vice President of R&D at Ancora Pharmaceuticals, successfully triaging the company through the acquisition and integration process by Corden Pharma. While at Surface Logix and Insmed, he played an integral role in the discovery and development of five clinical-stage drug candidates, including the Rho kinase inhibitor belumosudil (Rezurock™) and TAK-607 (rIGF-1/BP-3). During his career, Dr. Campbell has been a co-inventor on more than 20 issued patents.

He holds a B.S. with Honors in Chemistry from St. Francis Xavier University, a Ph.D. in Organic Chemistry from the Queen’s University (Canada) and completed his post-doctoral research at Duke University.

Ms. Moroni joined Axial in August 2019 and brings more than 20 years of corporate finance and accounting experience. She previously served as Controller at Eloxx Pharmaceuticals. Earlier in her career, she was a Senior Director at CFGI, a financial consulting firm, where she spent five years providing operational support to clients in the life sciences industry including Juniper Pharmaceuticals and Aveo Pharmaceutical. Ms. Moroni began her career at Arthur Andersen. She holds an M.B.A./M.S.A. in Accounting from Northeastern University and a B.A. from the College of the Holy Cross and holds Certified Public Accountant status in Massachusetts.

Mr. Young brings over 20 years of finance and capital markets experience, an extensive background in financial planning and operations, management and strategy, and a deep knowledge of the life sciences sector. Mr. Young most recently served as CFO, Treasurer and Secretary at Juniper Pharmaceuticals, Inc., where he played an instrumental role in Juniper’s acquisition by Catalent. Prior to that, Mr. Young served as CFO and Treasurer of OvaScience, a global fertility company focused on new treatment options for women. Mr. Young was previously the CFO and Treasurer of Transmedics, a developer of medical devices for the maintenance and transport of organs between donors and recipients. Before that, he served as CFO and Treasurer at Lantheus Medical Imaging, where he led and managed multiple public debt offerings.

​

Mr. Young began his career holding various positions of increasing responsibility in finance at Critical Therapeutics, PerkinElmer, Inc. and PriceWaterhouseCoopers LLP.  Mr. Young holds a Bachelor of Science in Business Administration from Georgetown University.